ライフサイエンスコーパス: phase 3 clinical trial

1 limentary Tract Cancer (PETACC)-8 randomized phase 3 clinical trial.

2 9m)Tc-MIP-1404, which has recently entered a phase 3 clinical trial.

3 markers to inform the design of a definitive phase 3 clinical trial.

4 the development of the drug in a randomized phase 3 clinical trial.

5 linical trial, clinical trials, phase 3, and phase 3 clinical trial.

6 ncept will need to be tested in a randomized phase 3 clinical trial.

7 an extended release formulation suitable for phase 3 clinical trials.

8 icing to treat spinal muscular atrophy is in phase 3 clinical trials.

9 strategies; this strategy is being tested in phase 3 clinical trials.

10 ocytic leukemia (CLL) based on 3 randomized, phase 3 clinical trials.

11 that have been approved or are currently in phase 3 clinical trials.

12 ent of the clinical development programme to phase 3 clinical trials.

13 l) for recurrent CDI using data from 2 large phase 3 clinical trials.

14 ch to treat Alzheimer's disease currently in phase 3 clinical trials.

15 wever be confirmed by the ongoing randomized phase 3 clinical trials.

16 Inhibition of PCSK9 warrants assessment in phase 3 clinical trials.

17 itis C virus (HCV(a)) NS3-4A protease, is in phase 3 clinical trials.

18 the lower dose should be further examined in phase 3 clinical trials.

19 high in quality (79%) compared with 70% for phase 3 clinical trials, 67% for translational research,

20 c driver mutations," "clinical trials," and "phase 3 clinical trials." Abstracts at scientific meetin

21 The Canadian Cancer Trials Group MA.31 phase 3 clinical trial accrued patients from 21 countrie

22 nes for susceptibility testing of BAL9141 in phase 3 clinical trials and after U.S.

23 20,000 closely monitored patients treated in phase 3 clinical trials and cohort studies.

24 ew iron chelators are in development, one in phase 3 clinical trials and the other in preliminary ani

25 ib, a CETP inhibitor that has been tested in phase 3 clinical trials, and compound 2, an analog from

26 een made based on the phase 2 trial results; phase 3 clinical trials are ongoing.

27 It is currently being tested in phase 3 clinical trials as maintenance therapy in ovaria

28 ic profile compared to 6 and was explored in phase 3 clinical trials as the phosphonooxymethyl deriva

29 t is currently being developed in an ongoing phase 3 clinical trial assessing its safety and efficacy

30 t is currently being developed in an ongoing phase 3 clinical trial assessing safety and efficacy to

31 The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicen

32 A phase 3 clinical trial (BMT CTN 0402) comparing tacrolim

33 Indeed, recent phase 3 clinical trials combining ivacaftor (a gating po

34 ium difficile isolates were collected from 2 phase 3 clinical trials comparing fidaxomicin to vancomy

35 p, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from J

36 is trial serve as a foundation for the large phase 3 clinical trial designed to assess both efficacy

37 This may facilitate the development of phase 3 clinical trials designed to more rigorously eval

38 This randomised, open-label, multicentre, phase 3 clinical trial enrolled patients with relapsed o

39 This randomized phase 3 clinical trial evaluated the potential benefit o

40 Gill et al describe the results of the first phase 3 clinical trial evaluating recombinant von Willeb

41 Unlike previous phase 2 trials, this phase 3 clinical trial failed to demonstrate a significa

42 However, two multicenter phase 3 clinical trials failed to show that beta2AR agon

43 In phase 3 clinical trials, fidaxomicin was well tolerated,

44 =0.5) and serial GMI during treatment from a phase 3 clinical trial for the treatment of invasive mol

45 al agents, and the absence of interventional phase 3 clinical trials for guidance of evidence-based d

46 of these strategies to rigosertib, a drug in phase 3 clinical trials for high-risk myelodysplastic sy

47 Compound 21 (ICA-17043) was advanced into phase 3 clinical trials for SCD.

48 w oral anticoagulants studied in the pivotal phase 3 clinical trials for stroke prevention or systemi

49 No successful phase 3 clinical trials for this disorder have been comp

50 ugs and biologics when only a single pivotal phase 3 clinical trial has provided such evidence.

51 inhibiting the protein directly, phase 2 and phase 3 clinical trials have demonstrated success in inh

52 A randomized phase 3 clinical trial in 17 Canadian centers.

53 ign, Setting, and Participants: A randomized phase 3 clinical trial in 17 Canadian centers.

54 ouble-blind, placebo-controlled, multicenter phase 3 clinical trial in patients with severe sepsis (t

55 CV GT1-infected subjects and is currently in phase 3 clinical trials in combination with an NS3 prote

56 tive CCR9 antagonist vercirnon progressed to phase 3 clinical trials in Crohn's disease but efficacy

57 Data from the comparator arms of four phase 3 clinical trials in first-line metastatic castrat

58 ks after the end of treatment (SVR12) in two phase 3 clinical trials in subjects previously treated w

59 e used in design, analyses, and reporting of phase 3 clinical trials in this disease.

60 Phase 3 clinical trials investigating first- and second-

61 of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling sup

62 ficant survival benefits in large randomized phase 3 clinical trials, leading to FDA approval.

63 SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Orga

64 mary and 14.3% metastatic) from the EGF30008 phase 3 clinical trial (NCT00073528), in which postmenop

65 ndomized, and treated within the multicenter phase 3 clinical trial NHL1-2003 comparing bendamustine-

66 The phase 3 clinical trial of etanercept confirmed its effic

67 During a phase 3 clinical trial of rhesus monkey rotavirus-based

68 n and cardiovascular disease archived from a phase 3 clinical trial of tofacitinib and etanercept in

69 ndomized, double-masked, placebo-controlled, phase 3 clinical trials of a single intravitreous inject

70 ith relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to g

71 atients with IBD, including two cohorts from phase 3 clinical trials of infliximab and golimumab, hig

72 Across 11 phase 3 clinical trials of ledipasvir-sofosbuvir (SOF) a

73 of patients with type 2 diabetes enrolled in phase 3 clinical trials of non-vitamin K antagonist oral

74 ul as an intervention for sepsis in a recent phase 3 clinical trial (PROWESS).

75 Furthermore, results from noninferiority phase 3 clinical trials randomizing early-stage HL patie

76 scence in situ hybridization for del17p in a phase 3 clinical trial (REACH [Rituximab in the Study of

77 For non-small-cell lung cancer, phase 3 clinical trial results of Toll-like receptor ago

78 Within 2 randomized, double-masked, phase 3 clinical trials (RIDE [A Study of Ranibizumab In

79 Three recent phase 3 clinical trials showed that inactivated monovale

80 Two multicenter, randomized, masked, phase 3 clinical trials (studies TG-MV-006 [between Dece

81 atched observational cohort with that of the phase 3 clinical trial suggests that these results can b

82 In 2 phase 3 clinical trials, telavancin was noninferior to v

83 blic health concerns were raised by a recent phase 3 clinical trial that showed that nonoxynol-9 (N-9

84 randomized, double-blind, placebo-controlled phase 3 clinical trial that took place between June 10,

85 first successful North American confirmatory phase 3 clinical trial to demonstrate the safety and eff

86 d two multicenter, randomized, double-blind, phase 3 clinical trials to compare a single intravitreal

87 riants, we analyzed samples from patients in phase 3 clinical trials to determine the frequency and r

88 In this phase 3 clinical trial we recruited patients aged 18 yea

89 e-blind, placebo-controlled, parallel-group, phase 3 clinical trial, we enrolled patients between Oct

90 The results of a recent phase 3 clinical trials with high-dose antithrombin in s

91 Several ongoing phase 3 clinical trials with novel therapies will furthe